Prognostic Significance of Circulating Tumor Cells with Mesenchymal Phenotypes in Patients with Gastric Cancer: A Prospective Study

被引:11
作者
Ishiguro, Yui [1 ]
Sakihama, Hideyasu [1 ]
Yoshida, Tadashi [1 ]
Ichikawa, Nobuki [1 ]
Homma, Shigenori [1 ]
Fukai, Moto [1 ]
Kawamura, Hideki [1 ]
Takahashi, Norihiko [1 ]
Taketomi, Akinobu [1 ]
机构
[1] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol Surg 1, Sapporo, Hokkaido, Japan
关键词
ADJUVANT CHEMOTHERAPY; RELEVANCE; PROSTATE; S-1;
D O I
10.1245/s10434-020-08827-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Circulating tumor cells (CTCs) have been shown to be heterogeneous. Focusing on the epithelial-mesenchymal transition and perioperative kinetics, we evaluated CTCs with mesenchymal phenotypes as a potential prognostic biomarker for patients with gastric cancer. Methods Peripheral blood was collected from 54 patients with gastric cancer before surgery and at 1 week and 1 month after surgery. CTCs were enriched using density-gradient centrifugation and magnetic-activated cell sorting (negative selection). Cell suspensions were characterized by multi-immunofluorescence staining against cytokeratin and N-cadherin, and by 4 ',6 '-diamidino-2-phenyldole staining. Results CTCs were detected in five patients (17%) with early cancer and 14 patients (56%) with advanced cancer (p < 0.05). In our system, N-cadherin, but not cytokeratin, was expressed in the CTCs of 90% (19/21) of patients. Postoperative recurrence was detected in 10 patients, all of whom had N-cadherin+/cytokeratin-/CD45- CTCs preoperatively. Regarding perioperative kinetics, we divided patients into three risk groups: a high-risk group, with one or more preoperative CTCs and increased CTCs postoperatively; an intermediate-risk group, with one or more preoperative CTCs and decreased CTCs postoperatively; and a low-risk group, with no preoperative CTCs. Recurrence rates were 57% (4/7), 33% (4/12), and 6% (2/35), respectively. The relapse-free survival rate was lower in patients at high risk versus those at intermediate or low risk, for all patients (p = 0.00024) and in patients with advanced cancer (p = 0.00103). Conclusions N-cadherin is a highly useful marker to detect CTCs lacking cytokeratin, and the perioperative kinetics of CTC numbers is beneficial in risk stratification for survival in patients with gastric cancer.
引用
收藏
页码:1178 / 1186
页数:9
相关论文
共 33 条
[1]   The Potential Clinical Implications of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer [J].
Abdallah, Emne A. ;
Braun, Alexcia C. ;
Flores, Bianca C. T. C. P. ;
Senda, Lais ;
Urvanegia, Ana Claudia ;
Calsavara, Vinicius ;
Fonseca de Jesus, Victor Hugo ;
Arruda Almeida, Maria Fernanda ;
Begnami, Maria Dirlei ;
Coimbra, Felipe J. F. ;
da Costa Jr, Wilson Luiz ;
Nunes, Diana Noronha ;
DiasNeto, Emmanuel ;
Domingos Chinen, Ludmilla T. .
ONCOLOGIST, 2019, 24 (09) :E854-E863
[2]   A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer [J].
Armstrong, Andrew J. ;
Shen, Tong ;
Halabi, Susan ;
Kemeny, Gabor ;
Bitting, Rhonda L. ;
Kartcheske, Patricia ;
Embree, Elizabeth ;
Morris, Karla ;
Winters, Carolyn ;
Jaffe, Tracy ;
Fleming, Mark ;
George, Daniel J. .
CLINICAL GENITOURINARY CANCER, 2013, 11 (04) :397-406
[3]   Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers [J].
Armstrong, Andrew J. ;
Marengo, Matthew S. ;
Oltean, Sebastian ;
Kemeny, Gabor ;
Bitting, Rhonda L. ;
Turnbull, James D. ;
Herold, Christina I. ;
Marcom, Paul K. ;
George, Daniel J. ;
Garcia-Blanco, Mariano A. .
MOLECULAR CANCER RESEARCH, 2011, 9 (08) :997-1007
[4]   Multiparameter Analysis, including EMT Markers, on Negatively Enriched Blood Samples from Patients with Squamous Cell Carcinoma of the Head and Neck [J].
Balasubramanian, Priya ;
Lang, James C. ;
Jatana, Kris R. ;
Miller, Brandon ;
Ozer, Enver ;
Old, Mathew ;
Schuller, David E. ;
Agrawal, Amit ;
Teknos, Theodoros N. ;
Summers, Thomas A., Jr. ;
Lustberg, Maryam B. ;
Zborowski, Maciej ;
Chalmers, Jeffrey J. .
PLOS ONE, 2012, 7 (07)
[5]   Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer [J].
Cristofanilli, M ;
Hayes, DF ;
Budd, GT ;
Ellis, MJ ;
Stopeck, A ;
Reuben, JM ;
Doyle, GV ;
Matera, J ;
Allard, WJ ;
Miller, MC ;
Fritsche, HA ;
Hortobagyi, GN ;
Terstappen, LWMM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) :1420-1430
[6]   Circulating tumor cells, disease progression, and survival in metastatic breast cancer [J].
Cristofanilli, M ;
Budd, GT ;
Ellis, MJ ;
Stopeck, A ;
Matera, J ;
Miller, MC ;
Reuben, JM ;
Doyle, GV ;
Allard, WJ ;
Terstappen, LWMM ;
Hayes, DF .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (08) :781-791
[7]   Detection and isolation of circulating tumor cells: Principles and methods [J].
Esmaeilsabzali, Hadi ;
Beischlag, Timothy V. ;
Cox, Michael E. ;
Parameswaran, Ash M. ;
Park, Edward J. .
BIOTECHNOLOGY ADVANCES, 2013, 31 (07) :1063-1084
[8]   Looking back, to the future of circulating tumor cells [J].
Friedlander, Terence W. ;
Premasekharan, Gayatri ;
Paris, Pamela L. .
PHARMACOLOGY & THERAPEUTICS, 2014, 142 (03) :271-280
[9]   Circulating tumor cells: Advances in isolation and analysis, and challenges for clinical applications [J].
Harouaka, Ramdane ;
Kang, Zhigang ;
Zheng, Si-Yang ;
Cao, Liang .
PHARMACOLOGY & THERAPEUTICS, 2014, 141 (02) :209-221
[10]   Prognostic significance of circulating tumor cells in patients with gastric cancer: Epithelial mesenchymal transition and perioperative kinetics. [J].
Ishiguro, Yui .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)